67Cu标记双价PSMA抑制剂的治疗疗效
该研究在PSMA阳性前列腺癌异种移植模型中评估67Cu-CuSarbisPSMA的治疗潜力,并与177Lu-LuPSMA成像与治疗进行比较。结果显示两种示踪剂在注射后13天均以剂量依赖方式相似地抑制肿瘤生长,单次30 MBq或分次2×15 MBq给药的生存期相当。结论认为67Cu-CuSarbisPSMA在PSMA表达的前列腺癌模型中有效。
要点
- 67Cu-CuSarbisPSMA在PSMA阳性模型中可剂量依赖性抑制肿瘤生长
- 注射后13天,67Cu与177Lu示踪剂对肿瘤生长的抑制相似
- 单次30 MBq与分次2×15 MBq给药的生存期相当
核心结论
- 67Cu-CuSarbisPSMA在PSMA表达的前列腺癌模型中具有治疗疗效。
研究设计与样本
- 在PSMA阳性异种移植模型中评估67Cu-CuSarbisPSMA或177Lu-LuPSMA成像与治疗后的肿瘤生长。
主要发现
- 注射后13天,两种示踪剂均以剂量依赖方式相似地抑制肿瘤生长。
关键数值与推荐
- 单次30 MBq或分次2×15 MBq(间隔2周)给药后生存期相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA. Methods: Growth of PSMA-positive xenografts was evaluated after treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA imaging and therapy (I&T). Results: At 13 d after injection, tumor growth was similarly inhibited by the 2 tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated (2 × 15 MBq, 2 wk apart) administrations. Conclusion:67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer.
引用
- McInnes LE, Cullinane C, Roselt PD, et al. Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with 67Cu. J Nucl Med. 2020. PMID: 33067341. doi:10.2967/jnumed.120.251579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。